Merck & Co., Inc. (MRK) Aktie — ist das ein gutes Unternehmen?

Merck & Co., Inc. (MRK) Aktie — ist das ein gutes Unternehmen? — InspectStocks

Just reported

Q3 2026 results

From Merck's results release of 29. Oktober 2026; its quarterly report has since been filed.

Revenue
Actual
18,09B $
+4,7 % y/y
+8,9 % q/q
Guided
—
No guide given
EPS, GAAP
Actual
2,04 $
-12 % y/y
Guided
—
No guide given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

The full earnings report →

Womit das Unternehmen Geld verdient

Human medicines and vaccines (Pharmaceutical segment)90 %
Animal medicines, vaccines and related products (Animal Health segment)10 %

Die Umsatzanteile sind Schätzungen für FY2025 und keine Zahlen aus einem eingereichten Bericht.

Konkurriert mit

Was es verkauft6

Keytruda and Keytruda Qlex
Cancer medicines. Keytruda is given into a vein; Keytruda Qlex is a form given as an injection under the skin.
Gardasil and Gardasil 9
Vaccines that help prevent certain cancers and other diseases caused by some types of human papillomavirus.
Januvia and Janumet
Prescription medicines used to help lower blood sugar in adults with type 2 diabetes.

3 weitere anzeigen

Winrevair
A medicine for adults with pulmonary arterial hypertension, a disease that raises blood pressure in the arteries from the heart to the lungs.
Lipfendra
An oral medicine used with diet and exercise to lower low-density lipoprotein cholesterol in adults with high cholesterol.
Bravecto
A range of medicines that protect dogs and cats against fleas and ticks, including oral, topical and injectable forms.

Wer es kauft5

Drug wholesalers and retailers buy Merck's human prescription medicines for distribution to pharmacies and other care providers.
Hospitals, government agencies and managed health-care organizations buy or arrange access to prescription medicines.
Physicians, wholesalers, distributors and government entities buy or distribute Merck's human vaccines.

2 weitere anzeigen

Veterinarians, animal-health distributors, animal producers and farmers buy veterinary medicines, vaccines and animal monitoring products.
Pet owners buy Merck's companion-animal products, sometimes through veterinary practices or distributors.

Worauf es steht, und was es umwerfen könnte

Wovon das Geschäft abhängt

1Sales depend heavily on a small number of major medicines. Keytruda was Merck's biggest-selling product in 2025, and sales depend on continued demand, market access and patent protection.
2Merck depends on patents and other legal protections for medicines. When products lose market exclusivity, generic or biosimilar versions can take sales; the 2026 quarterly report describes this pressure on Januvia, Janumet and Bridion.
3Sales depend on regulatory approval, health-care coverage and government and insurer purchasing decisions. The company also reports that certain raw or intermediate materials come primarily from a single supplier.
4Gardasil sales in China depend on demand and the relationship with its Chinese distributor and commercialization partner; Merck suspended shipments in 2025 and resumed limited shipments in 2026.

Was schiefgehen könnte

1Merck identifies its dependence on patent rights as a risk: if patents are invalidated or products lose market exclusivity, generic or biosimilar competition can rapidly reduce sales. Keytruda is its biggest-selling product, and the company reports that U.S. government price-setting for certain medicines is also affecting its business.
2Government and private health-care cost controls can lower prices or restrict access. The latest quarterly report describes price-setting, Medicaid discounts and other cost-reduction measures, including a German health-care reform law expected to put downward pressure on sales there.
3Vaccine sales can be affected by changes in vaccination recommendations, government purchasing and demand. Gardasil sales fell in China, where Merck suspended shipments before agreeing to limited shipments under a revised distributor contract; U.S. childhood immunization schedule changes were also subject to a court injunction and government appeal.

Vollständige Abschlüsse →

Über Merck & Co., Inc.

Merck discovers, develops, manufactures and sells prescription medicines and vaccines for people, including cancer treatments such as Keytruda and vaccines such as Gardasil. Its Animal Health business sells medicines, vaccines and animal identification and monitoring products to veterinarians, farmers and other animal-care businesses.

Hauptsitz: Rahway, New Jersey, United States
Gegründet: 1891
Notiert an: NYSE
Geschäftsjahresende: December 31

Gebaut aus den eigenen Einreichungen von Merck & Co., Inc. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.

Just reported

Q3 2026 results

From Merck's results release of 29. Oktober 2026; its quarterly report has since been filed.

Revenue
Actual
18,09B $
+4,7 % y/y
+8,9 % q/q
Guided
—
No guide given
EPS, GAAP
Actual
2,04 $
-12 % y/y
Guided
—
No guide given

The full earnings report →

Keep exploring

The themes Merck is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Highest-graded in Drug Manufacturers General

Graded A or B and worth $2B or more: A first, then the largest.

All 19 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises